TaiMed Biologics

TaiMed Biologics Inc. (4147.TWO) is a prominent Taiwanese biopharmaceutical company, established in 2007. With extensive expertise in developing and manufacturing monoclonal antibodies (mAb), TaiMed has reached a significant achievement by launching Trogarzo® (TMB-355), the first and only mAb for HIV treatment in the US and Europe, into the market. The company focuses on providing comprehensive services tailored to support the pharmaceutical industry throughout the various stages of biopharmaceutical development and production.

Services include:
- Accelerated Stability Studies
- Analytical Services
- Assay Development
- Bioanalytical Services
- Biological Testing
- Biologics
- Process Development
- Bioprocess Validation
- Bioprocessing
- Disposable/Single-Use
- Biosimilars
- Chemical Analysis
- Chromatography
- Chemistry (CMC)
- Manufacturing
- Contract Development and Manufacturing (CDMO)
- Fermentation
- Forced Degradation Studies
- Formulation Development
- Mammalian Cell Culture
- Clinical Trial Materials
- Process Validation Studies
- Quality QA/QC
- Raw Materials Analysis
- Scale-Up
- Stability Studies
- Stability
- ICH
- Storage
- Validation

TaiMed Biologics continues to evolve and strengthen its position in the biopharmaceutical industry by providing innovative solutions and high-quality services. For more information, please visit taimedbiologics.com.